GEP20166489B - 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors - Google Patents
1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitorsInfo
- Publication number
- GEP20166489B GEP20166489B GEAP201313563A GEAP2013013563A GEP20166489B GE P20166489 B GEP20166489 B GE P20166489B GE AP201313563 A GEAP201313563 A GE AP201313563A GE AP2013013563 A GEAP2013013563 A GE AP2013013563A GE P20166489 B GEP20166489 B GE P20166489B
- Authority
- GE
- Georgia
- Prior art keywords
- indazole
- carboxamide compounds
- glycogen synthase
- synthase kinase
- beta inhibitors
- Prior art date
Links
- 150000008581 1H-indazole-3-carboxamides Chemical class 0.000 title abstract 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 title abstract 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12156292 | 2012-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20166489B true GEP20166489B (en) | 2016-06-10 |
Family
ID=47739223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201313563A GEP20166489B (en) | 2012-02-21 | 2013-02-07 | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9611249B2 (enExample) |
| EP (1) | EP2817302B1 (enExample) |
| JP (1) | JP6141331B2 (enExample) |
| KR (1) | KR20140130124A (enExample) |
| CN (1) | CN104093712B (enExample) |
| AR (1) | AR090086A1 (enExample) |
| AU (1) | AU2013224302B2 (enExample) |
| BR (1) | BR112014018655B1 (enExample) |
| CA (1) | CA2860250C (enExample) |
| CY (1) | CY1117469T1 (enExample) |
| DK (1) | DK2817302T3 (enExample) |
| EA (1) | EA024939B1 (enExample) |
| ES (1) | ES2564961T3 (enExample) |
| GE (1) | GEP20166489B (enExample) |
| HR (1) | HRP20160125T1 (enExample) |
| HU (1) | HUE026893T2 (enExample) |
| IL (1) | IL233824A (enExample) |
| ME (1) | ME02353B (enExample) |
| MX (1) | MX351287B (enExample) |
| PL (1) | PL2817302T3 (enExample) |
| RS (1) | RS54567B1 (enExample) |
| SG (2) | SG11201403602WA (enExample) |
| SI (1) | SI2817302T1 (enExample) |
| SM (1) | SMT201600053B (enExample) |
| UA (1) | UA112564C2 (enExample) |
| WO (1) | WO2013124158A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860466C (en) * | 2012-02-21 | 2020-02-18 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S.P.A. | Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2942687A1 (en) | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| AU2017272505B9 (en) | 2016-06-01 | 2021-10-28 | Bayer Pharma Aktiengesellschaft | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| CN109563071B (zh) * | 2016-06-08 | 2021-08-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4途径抑制剂的化学化合物 |
| SG11202008029UA (en) * | 2018-02-23 | 2020-09-29 | Samumed Llc | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
| IL278330B2 (en) | 2018-05-07 | 2024-06-01 | Acraf | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| IL279155B2 (en) | 2018-06-05 | 2025-02-01 | Actuate Therapeutics Inc | Methods for treating malignant lymphoid tissue proliferation disorders |
| US12084426B2 (en) | 2018-09-13 | 2024-09-10 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| EA202190718A1 (ru) | 2018-09-13 | 2021-07-01 | Бристол-Маерс Сквибб Компани | Индазолкарбоксамиды в качестве ингибиторов киназ |
| US20240051939A1 (en) * | 2020-12-08 | 2024-02-15 | Disarm Therapeutics, Inc. | Benzopyrazole inhibitors of sarm1 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705498A (en) | 1992-11-05 | 1998-01-06 | Smithkline Beecham Plc. | Piperidine derivatives as 5-HT4 receptor antagonists |
| IT1291569B1 (it) * | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| EP1546156A1 (en) * | 2002-08-10 | 2005-06-29 | Astex Technology Limited | 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| ITMI20030287A1 (it) | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| ITMI20030972A1 (it) | 2003-05-15 | 2004-11-16 | Acraf | Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende. |
| WO2005014554A1 (en) * | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| GB0414438D0 (en) * | 2004-06-28 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| EP1692939A1 (en) * | 2005-02-19 | 2006-08-23 | Bayer CropScience S.A. | Pesticidal substituted piperidines |
| WO2008154241A1 (en) * | 2007-06-08 | 2008-12-18 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
| UA99927C2 (uk) | 2007-11-12 | 2012-10-25 | Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. | Медикамент, який є активним при невропатичному болі |
| US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US7947728B1 (en) * | 2009-11-11 | 2011-05-24 | Hoffmann-La Roche Inc. | Indole and indazole analogs as glycogen synthase activators |
-
2013
- 2013-02-07 MX MX2014009297A patent/MX351287B/es active IP Right Grant
- 2013-02-07 EP EP13704910.2A patent/EP2817302B1/en active Active
- 2013-02-07 ME MEP-2016-29A patent/ME02353B/me unknown
- 2013-02-07 BR BR112014018655-3A patent/BR112014018655B1/pt active IP Right Grant
- 2013-02-07 PL PL13704910T patent/PL2817302T3/pl unknown
- 2013-02-07 SG SG11201403602WA patent/SG11201403602WA/en unknown
- 2013-02-07 CA CA2860250A patent/CA2860250C/en active Active
- 2013-02-07 EA EA201491449A patent/EA024939B1/ru unknown
- 2013-02-07 DK DK13704910.2T patent/DK2817302T3/en active
- 2013-02-07 SG SG10201701649YA patent/SG10201701649YA/en unknown
- 2013-02-07 JP JP2014556989A patent/JP6141331B2/ja active Active
- 2013-02-07 KR KR20147022708A patent/KR20140130124A/ko not_active Ceased
- 2013-02-07 SI SI201330134T patent/SI2817302T1/sl unknown
- 2013-02-07 GE GEAP201313563A patent/GEP20166489B/en unknown
- 2013-02-07 CN CN201380007411.7A patent/CN104093712B/zh active Active
- 2013-02-07 WO PCT/EP2013/052400 patent/WO2013124158A1/en not_active Ceased
- 2013-02-07 HU HUE13704910A patent/HUE026893T2/en unknown
- 2013-02-07 US US14/373,100 patent/US9611249B2/en active Active
- 2013-02-07 HR HRP20160125TT patent/HRP20160125T1/hr unknown
- 2013-02-07 AU AU2013224302A patent/AU2013224302B2/en active Active
- 2013-02-07 ES ES13704910.2T patent/ES2564961T3/es active Active
- 2013-02-07 RS RS20160132A patent/RS54567B1/sr unknown
- 2013-02-19 AR ARP130100502A patent/AR090086A1/es active IP Right Grant
- 2013-07-02 UA UAA201406961A patent/UA112564C2/uk unknown
-
2014
- 2014-07-27 IL IL233824A patent/IL233824A/en active IP Right Grant
-
2016
- 2016-02-23 SM SM201600053T patent/SMT201600053B/xx unknown
- 2016-03-15 CY CY20161100219T patent/CY1117469T1/el unknown
-
2017
- 2017-02-22 US US15/439,172 patent/US10160746B2/en active Active
- 2017-03-07 US US15/451,966 patent/US20170174657A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20166489B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| IL268340A (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
| PH12016500582B1 (en) | Heterocyclic compounds and uses thereof | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| EP3030323A4 (en) | Kdm1a inhibitors for the treatment of disease | |
| HK1216175A1 (zh) | 治療性化合物和組合物 | |
| HK1245247A1 (zh) | 溴结构域的抑制剂 | |
| MX2015010125A (es) | Derivados de piridazinona-amidas. | |
| MX2017006302A (es) | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. | |
| PH12014500468A1 (en) | Heterocyclic compounds and uses thereof | |
| MX371312B (es) | Pirazolil-ureas como inhibidores de quinasas. | |
| EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
| PH12013501754A1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| IN2015DN01151A (enExample) | ||
| BR112018008931A2 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX364859B (es) | Derivados de imidazopirazinona. | |
| SG10201900954SA (en) | Heterocycles as Modulators of Kinase Activity | |
| EP2994156A4 (en) | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity |